Compare iShares Global Clean Energy ETF (ICLN) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Global Clean Energy ETF vs Regeneron Pharmaceuticals Inc — how do they compare? iShares Global Clean Energy ETF trades at $18.54, while Regeneron Pharmaceuticals Inc trades at $675 (market cap $70.47B). The key difference: Regeneron Pharmaceuticals Inc pays a 0.56% dividend while iShares Global Clean Energy ETF pays none. Which is the better fit depends on your goals.
| ICLN | REGN | |
|---|---|---|
52-Week High | $23.75 | $812.27 |
52-Week Low | $13.41 | $545.46 |
Market Cap | — | $70.47B |
Sector | — | Health |
Enterprise Value | — | $64.42B |
Dividend Yield | — | 0.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ICLN trades at $18.52, up 0.82% today, while technical indicators show a bearish trend with moving averages signaling sell pressure. The ETF holds 105 global clean energy companies, benefiting from AI-driven electricity demand and high oil prices, yet faces policy risks. Recent news highlights its 29% YTD return outperforming the S&P 500, with a P/E of 25.7x and long-term EPS growth of 9.1% as of Seeking Alpha on June 7, 2026.
Outlook is mixed: bullish momentum from energy transition trends supports growth, but regulatory uncertainties and high valuation pose risks. Investors may see opportunity in the clean energy sector's structural shift, though volatility from policy changes requires caution.
Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.
The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Global Clean Energy ETF
The index is designed to track the performance of approximately 100 clean energy-related companies. The fund generally invests at least 80% of its assets in the component securities of the target index. The index may invest up to 20% of its assets in certain futures, trading options and swap contracts, cash and cash equivalents, as well as in securities not included in the index. It is non-diversified.
Read more on ICLN →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
